Home / Resources / Scrip Asks: What Does 2025 Hold for Biopharma?
Scrip Asks: What Does 2025 Hold for Biopharma?

More than 40 industry executives shared their views on where the biopharma industry stood as it entered the new year. Innovation remained the sector’s driving force, but after two years of capital constraint, due diligence is key.

Download the eBook to learn more.

''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.
… [C]linical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.
Scott Schliebner, Vice President and Global Head, Drug Development Consulting, Novotech
Related products
Professionals accessing Scrip for the latest industry news and developments to gain advantage on competition.
Scrip
Global pharmaceutical industry news that goes beyond the headlines
Expert interview with a biopharma leader for insights and strategy.
In Vivo
Interviews, analysis and critical insights for life science decision-makers
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape

Related resources

''
JAN 15, 2025
eBook
Commercial

Outlook 2025: Key Trends & Insights

Outlook 2025 dives into the key trends shaping the year ahead, from geopolitical issues to cutting-edge innovation in AI, oncology, and weight loss.

Report cover for TechBio
OCT 17, 2024
Report
Commercial

TechBio: UK Leads Innovation Frontier

TechBio sits at the intersection of data, AI, life science and innovation. This report highlights key companies, deals, and approaches across TechBio.

A variety of pills and tablets arranged neatly on a wooden table surface
OCT 09, 2024
Report
Commercial

Key Potential Drug Launches in 2025

Biomedtracker’s Key Potential Drug Launches in 2025 report provides a longer-term look at some key late-stage drugs projected to hit the market in 2025.

View all